Format

Send to

Choose Destination
Curr Rheumatol Rep. 2016 Dec;18(12):76. doi: 10.1007/s11926-016-0625-5.

Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.

Author information

1
Division of Rheumatology, McGill University Health Centre, Montréal, Quebec, Canada. mary-ann.fitzcharles@muhc.mcgill.ca.
2
Alan Edwards Pain Management Unit, McGill University Health Centre, Montréal, Quebec, Canada. mary-ann.fitzcharles@muhc.mcgill.ca.
3
Montreal General Hospital, McGill University Health Centre, 1650 Cedar ave, Montreal, Quebec, H3G 1A4, Canada. mary-ann.fitzcharles@muhc.mcgill.ca.
4
Department Internal Medicine I, Klinikum Saarbrücken, Saarbrücken, Germany.
5
Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany.

Abstract

The endocannabinoid system impacts pain and inflammation with potential for therapeutic effect on patients with rheumatic diseases. The current treatment options include the herbal product derived from the plant Cannabis sativa, as well as pharmaceutical preparations. The legalization of medicinal cannabis (marijuana) in many jurisdictions and widespread public advocacy has propelled an interest in use either by prescription or self-medication. In this review, we examine current evidence for efficacy and adverse effects of any cannabinoid product in rheumatic conditions. The evidence to date is scant and precludes making recommendations for the use of cannabinoid preparations in rheumatology patients. In particular, the risks of herbal cannabis in patients are not well defined. Anecdote and advocacy cannot supersede sound evidence.

KEYWORDS:

Cannabinoids; Marijuana; Rheumatic disease

PMID:
27832442
DOI:
10.1007/s11926-016-0625-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center